MedTrace Logo

A Study of LAM-002A for the Prevention of Progression of COVID-19

NCT04446377 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 142

Last updated 2023-08-08

Study results available
· View outcomes & findings →

Summary

This is a clinical trial to evaluate the efficacy of LAM-002A compared to placebo treatment in adults with a confirmed SARS-CoV-2 infection who are receiving standards supportive care in an outpatient setting.

Conditions

  • COVID-19 Disease

Interventions

DRUG

Apilimod Dimesylate Capsule

LAM-002A is formulated in capsules containing 25 mg of apilimod dimesylate. The capsule is Swedish orange, Size 0.

OTHER

Placebo

Microcrystalline cellulose in Swedish orange, Size 0 capsules

Sponsors & Collaborators

  • Yale University

    collaborator OTHER

  • OrphAI Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-15
Primary Completion
2021-03-24
Completion
2021-04-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04446377 on ClinicalTrials.gov